399 related articles for article (PubMed ID: 29130362)
41. Low serum levels of uric acid and albumin in patients with Guillain-Barre syndrome.
Su Z; Chen Z; Xiang Y; Wang B; Huang Y; Yang D; Li X; Weng Y; Lin X; Chen G; Liu W; Zhao C; Wang Q; Li S; Chen Y; Chen Y; Quan W; Tong Q; Wu S; Huang S; Mei P; Li Z; Li J; Hou S; Zhang X
Medicine (Baltimore); 2017 Apr; 96(15):e6618. PubMed ID: 28403109
[TBL] [Abstract][Full Text] [Related]
42. Plasma cortisol levels in Guillain-Barré syndrome.
Strauss J; Aboab J; Rottmann M; Porcher R; Polito A; Ikka L; Durand MC; Orlikowski D; Devaux C; Lofaso F; Annane D; Gaillard JL; Sharshar T
Crit Care Med; 2009 Aug; 37(8):2436-40. PubMed ID: 19531948
[TBL] [Abstract][Full Text] [Related]
43. Bilateral Ptosis due to Sympathetic Dysfunction as a Feature of Guillain-Barre Syndrome.
Panosyan FB
J Clin Neuromuscul Dis; 2017 Sep; 19(1):38-42. PubMed ID: 28827488
[TBL] [Abstract][Full Text] [Related]
44. Guillain-Barré and Miller Fisher syndromes in patients with anti-hepatitis E virus antibody: a hospital-based survey in Japan.
Fukae J; Tsugawa J; Ouma S; Umezu T; Kusunoki S; Tsuboi Y
Neurol Sci; 2016 Nov; 37(11):1849-1851. PubMed ID: 27389141
[TBL] [Abstract][Full Text] [Related]
45. Guillain-Barré syndrome in the elderly.
Peric S; Berisavac I; Stojiljkovic Tamas O; Rajic S; Babic M; Cvijanovic M; Dominovic-Kovacevic A; Basta I; Beslac-Bumbasirevic L; Lavrnic D
J Peripher Nerv Syst; 2016 Jun; 21(2):105-10. PubMed ID: 26880714
[TBL] [Abstract][Full Text] [Related]
46. Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies.
Odaka M; Yuki N; Tatsumoto M; Tateno M; Hirata K
J Neurol; 2004 Jan; 251(1):24-9. PubMed ID: 14999485
[TBL] [Abstract][Full Text] [Related]
47. Mannose-binding Lectin Mediated Complement Pathway in Autoimmune Neurological Disorders.
Farrokhi M; Dabirzadeh M; Dastravan N; Etemadifar M; Ghadimi K; Saadatpour Z; Rezaei A
Iran J Allergy Asthma Immunol; 2016 Jun; 15(3):251-6. PubMed ID: 27424141
[TBL] [Abstract][Full Text] [Related]
48. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
[TBL] [Abstract][Full Text] [Related]
49. Hyponatraemia in Guillain-Barré syndrome revisited.
Hiew FL; Winer JB; Rajabally YA
Acta Neurol Scand; 2016 Apr; 133(4):295-301. PubMed ID: 26184092
[TBL] [Abstract][Full Text] [Related]
50. Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain-Barré syndrome.
Kharwar NK; Prasad KN; Singh K; Paliwal VK; Modi DR
Int J Neurosci; 2017 Aug; 127(8):680-687. PubMed ID: 27595159
[TBL] [Abstract][Full Text] [Related]
51. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
[TBL] [Abstract][Full Text] [Related]
52. Serum thyroid-stimulating hormone is an independent risk factor of recurrent Guillain-Barré syndrome.
Wang S; Luo Z; Peng T
Muscle Nerve; 2022 Jun; 65(6):688-692. PubMed ID: 35342963
[TBL] [Abstract][Full Text] [Related]
53. The analysis of serum lipids profile in Guillain-Barre syndrome.
Wang L; Ding Y; Liu J; Zheng G; Li S; Jiang W; Chen K; Luan X; Chen Y; Wang S; Zhang G
Front Immunol; 2023; 14():1301577. PubMed ID: 38143756
[TBL] [Abstract][Full Text] [Related]
54. [Relationship between parenteral gangliosides administration and the Guillain-Barré syndrome].
Conceição I; Carvalho M; Alves M; Parreira E; Martins A; Ferro J; Sales-Luis ML
Rev Neurol; 1999 Jun 1-15; 28(11):1033-5. PubMed ID: 10390766
[TBL] [Abstract][Full Text] [Related]
55. Clinical predictors and electrodiagnostic characteristics in patients with Guillain-Barré syndrome with respiratory failure: a retrospective, matched case-control study.
Charoentanyarak K; Singjam A; Saengsuwan J
PeerJ; 2022; 10():e12930. PubMed ID: 35186497
[TBL] [Abstract][Full Text] [Related]
56. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh.
Islam Z; Jacobs BC; van Belkum A; Mohammad QD; Islam MB; Herbrink P; Diorditsa S; Luby SP; Talukder KA; Endtz HP
Neurology; 2010 Feb; 74(7):581-7. PubMed ID: 20157160
[TBL] [Abstract][Full Text] [Related]
57. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS).
Verma R; Chaudhari TS; Raut TP; Garg RK
J Neurol Sci; 2013 Dec; 335(1-2):105-11. PubMed ID: 24064258
[TBL] [Abstract][Full Text] [Related]
58. Increased cerebrospinal fluid protein and motor conduction studies as prognostic markers of outcome and nerve ultrasound changes in Guillain-Barré syndrome.
Kerasnoudis A; Pitarokoili K; Behrendt V; Gold R; Yoon MS
J Neurol Sci; 2014 May; 340(1-2):37-43. PubMed ID: 24607336
[TBL] [Abstract][Full Text] [Related]
59. The clinical significance of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in Guillain-Barré syndrome.
Huang Y; Ying Z; Quan W; Xiang W; Xie D; Weng Y; Li X; Li J; Zhang X
Int J Neurosci; 2018 Aug; 128(8):729-735. PubMed ID: 29251087
[TBL] [Abstract][Full Text] [Related]
60. Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain-Barré syndrome.
Ozdemir HH
Arq Neuropsiquiatr; 2016 Sep; 74(9):718-722. PubMed ID: 27706420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
